// App-Quantinova.ai

652 : Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Dong-Wook Kim

  • Yesid Alvarado

  • Franck E Nicolini

  • Navin Khattry

  • Krishnakumar Rathnam

  • Jane Apperley

  • Michael W. Deininger

  • Hugues de Lavallade

  • Aude Charbonnier

  • Nikki Granacher

  • Carlo Gambacorti-Passerini

  • Alessandro Lucchesi

  • Michael J. Mauro

  • Gregor Verhoef

  • Peter Vandenberghe

  • Andrew R. Whiteley

  • Shashikant Apte

  • Siu-Long Yao

  • Mudgal Kothekar

  • Jayasree Sreenivasan

  • Bimba HV

  • Geetanjali Chimote

Medical Centers

  • Georgia Cancer Center, Augusta University, Augusta, GA

  • Prince Aly Khan Hospital, Mumbai, India

  • Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of

  • Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea,

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Hematology department & ISERM U590, Centre Hospitalier Lyon Sud, LYON Cedex 03, France

  • BMT unit, Department of Medical oncology, ACTREC., Tata Memorial Centre, Navi Mumbai, India

  • Lake Area,Melur Main Rd, Meenakshi Mission Hospital and Research Centre, Tamil Nadu, India

  • Centre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College, London, United Kingdom

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Onco-Hematology Department, Paoli-Calmette Cancer Institute, Marseille, France

  • Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium

  • Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Center for Human Genetics, University of Leuven Center for Human Genetics, Leuven, Belgium

  • Baylor University Medical Center, Dallas, TX

  • Department of Haematology, Sahyadri Speciality Hospital, Pune, India

  • Sun Pharmaceutical Industries, Princeton, NJ

  • Clinical Research Department, Sun Pharma Advanced Research Company, Mumbai, Maharashtra, India

Locations

  • United States

  • India

  • Republic of South Korea

  • France

  • United Kingdom

  • Belgium

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Vodobatinib

  • Ponatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02629692

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved